Maxim Group Cuts Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target to $3.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective decreased by Maxim Group from $5.00 to $3.00 in a research report sent to investors on Friday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Other analysts also recently issued research reports about the company. HC Wainwright raised their price target on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. D. Boral Capital reissued a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Lineage Cell Therapeutics currently has an average rating of “Buy” and an average price target of $4.80.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $0.58 on Friday. Lineage Cell Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.61. The company has a market cap of $127.84 million, a PE ratio of -4.83 and a beta of 1.16.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in LCTX. Geode Capital Management LLC raised its holdings in shares of Lineage Cell Therapeutics by 2.3% during the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock worth $3,331,000 after acquiring an additional 83,274 shares during the period. State Street Corp increased its holdings in Lineage Cell Therapeutics by 1.8% during the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after purchasing an additional 45,483 shares in the last quarter. Barclays PLC raised its stake in shares of Lineage Cell Therapeutics by 311.3% in the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after purchasing an additional 159,924 shares during the period. Raffles Associates LP lifted its holdings in shares of Lineage Cell Therapeutics by 35.8% in the second quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock valued at $4,346,000 after purchasing an additional 1,147,800 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Lineage Cell Therapeutics by 35.7% during the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock worth $435,000 after buying an additional 114,762 shares during the period. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.